The LRP6 rs2302685 polymorphism is associated with increased risk of myocardial infarction
© Xu et al.; licensee BioMed Central Ltd. 2014
Received: 12 April 2014
Accepted: 27 May 2014
Published: 7 June 2014
Abnormal lipids is one of the critical risk factors for myocardial infarction (MI), however the role of genetic variants in lipid metabolism-related genes on MI pathogenesis still requires further investigation. We herein genotyped three SNPs (LRP6 rs2302685, LDLRAP1 rs6687605, SOAT1 rs13306731) in lipid metabolism-related genes, aimed to shed light on the influence of these SNPs on individual susceptibility to MI.
Genotyping of the three SNPs (rs2302685, rs6687605 and rs13306731) was performed in 285 MI cases and 650 control subjects using polymerase chain reaction–ligation detection reaction (PCR–LDR) method. The association of these SNPs with MI and lipid profiles was performed with SPSS software.
Multivariate logistic regression analysis showed that C allele (OR = 1.62, P = 0.039) and the combined CT/CC genotype (OR = 1.67, P = 0.035) of LRP6 rs2302685 were associated with increased MI risk, while the other two SNPs had no significant effect. Further stratified analysis uncovered a more evident association with MI risk among younger subjects (≤60 years old). Fascinatingly, CT/CC genotype of rs2302685 conferred increased LDL-C levels compared to TT genotype (3.0 mmol/L vs 2.72 mmol/L) in younger subjects.
Our data provides the first evidence that LRP6 rs2302685 polymorphism is associated with an increased risk of MI in Chinese subjects, and the association is more evident among younger individuals, which probably due to the elevated LDL-C levels.
KeywordsLRP6 Single nucleotide polymorphism Myocardial infarction Risk
Myocardial infarction (MI) is a leading cause of death and morbidity worldwide, which is a main manifestation of coronary artery disease (CAD). Previous studies and clinical trials have established multiple risk factors contributing to the pathogenesis of MI, including obesity, hypercholesterolemia, smoking, alcohol intake, diabetes, hypertension, physical inactivity and psychosocial situation [1–3]. Among these, hypercholesterolemia arising from abnormal lipid metabolism has been considered to be one of the most key risk factors for MI [4, 5]. What’s more, apart from above modifiable risk factors, a growing body of studies have demonstrated close associations of genetic variants in candidate genes with the risk of MI, suggesting that host genetic backgrounds exert critical roles on MI pathogenesis as well [6–8].
Low density lipoprotein receptor-related protein 6 (LRP6), a member of the LRP family of type I transmembrane proteins, functions as a co-receptor with Frizzled proteins for Wnt ligands, and thus plays a critical role in the regulation of multiple cellular processes, and the development of many human diseases [9–11]. Moreover, accumulating evidences have recently linked LRP6 genetically to early coronary artery disease and abnormal lipids including hypercholesterolemia [12–14]. Five functional mutations (K82N, S488Y, P1066T, P1206H and I1264V) within LRP6 gene have been identified in CAD patients, which might be contributing factors for CAD through significantly reduction in both LRP6 protein level and Wnt signal activity . Another mutation in LRP6 (R611C) has been identified in an Iranian family characterized with early CAD, features of the metabolic syndrome (hyperlipidemia, hypertension and diabetes), and osteoporosis , which significantly promoted PDGF-dependent vascular smooth muscle cells (VSMCs) proliferation compared to wild-type LRP6. Thus it was reasonable to speculate that LRP6 might probably play an important role in MI pathogenesis.
Low density lipoprotein receptor adaptor protein 1 (LDLRAP1) interacts with the cytoplasmic tail of LDL receptor and exerts a crucial role on LDL uptake via promoting LDL receptor clustering into clathrin-coated pits [18–21]. In addition, mutations in LDLRAP1 gene cause familial hypercholesterolemia (FH) characterized with severe hypercholesterolemia and premature coronary artery disease [22, 23]. Sterol O-acyltransferase 1 (SOAT1) is also named acyl-coenzyme A: cholesterol acyltransferase (ACAT), which esterifies cholesterol in a variety of tissues . Previous studies have demonstrated that SOAT1 was involved in the formation of atherosclerotic plaques, and thus might be a promising target for atherosclerosis and hypercholesterolemia treatment [25, 26]. In spite of the close association between these two genes and hypercholesterolemia, the effects of LDLRAP1 and SOAT1 polymorphisms on hypercholesterolemia and CAD remain largely unknown.
Single nucleotide polymorphism (SNP) has been established to influence individual susceptibility for numerous human diseases. A plethora of evidences have suggested that SNPs within the lipid metabolism-related genes might potentially contribute to MI risk [27–30]. Nonetheless, the genetic causes and underlying molecular mechanisms of these candidate genes for MI are still far to be elucidated. Thus, we herein conducted a case–control study to investigate the association of the three SNPs in the lipid metabolism-related genes (rs2302685 in LRP6, rs6687605 in LDLRAP1 and rs13306731 in SOAT1) with the risk of MI. Our data revealed that the C allele of rs2302685 in LRP6 has a significant association with an increased risk of MI in a Chinese population, which probably due to the elevated LDL-C levels.
285 MI patients and 650 control subjects were consecutively recruited from the First People’s Hospital of Foshan (Foshan, China) and the Affiliated Hospital of Guangdong Medical College (Zhanjiang, China) from March 2011 to February 2013. The diagnosis of MI was based on typical electrocardiographic changes and on increases in the serum cardiac markers, such as creatinine kinase, aspartate aminotransferase, lactate dehydrogenase and troponin T. The diagnosis was confirmed by the identification of the responsible stenosis in any of the major coronary arteries or in the left main trunk by coronary angiography. Subjects with a history of hematologic, neoplastic, renal, liver, or thyroid diseases were excluded. The unaffected controls were judged to be free of MI by questionnaires, medical history, clinical examination and electrocardiography.
All subjects enrolled in this study were genetically unrelated ethnic Han Chinese. Each subject was interviewed to collect information on demographic data and risk factors related to MI after obtaining the informed consent. The study was approved by the Medical Ethics Committee of the First People’s Hospital of Foshan and the Affiliated Hospital of Guangdong Medical College.
Biochemical parameters analysis
The blood sample drawn from each subject was centrifuged at 2000 × g for 15 min immediately after collection and stored at −80°C. The levels of plasma total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) were measured enzymatically using a chemistry analyzer (Olympus, Japan). Glucose was analyzed by the glucose oxidase method with an Abbott V/P Analyzer (Abbott Laboratories, USA).
Genomic DNA was extracted from peripheral whole blood by TIANamp blood DNA extraction kit (TianGen Biotech, Beijing, China) according to the manufacturer’s instructions. All DNA samples were dissolved in water and stored at −20°C until use.
SNPs genotyping were performed utilizing polymerase chain reaction-ligase detection reaction (PCR-LDR) method (Shanghai Biowing Applied Biotechnology Company), as described in our previous study . The sequence of primers and probes were listed in Additional file 1: Table S1.
All the three SNPs were tested for confirmation with Hardy-Weinberg expectations by a goodness-of-fit χ2 test among the control subjects. Quantitative variables were expressed as mean ± standard deviation (SD), and qualitative variables were expressed as percentages. The differences of the demographic characteristics between the cases and controls were estimated using the χ2 test (for categorical variables) and Student’s t test (for continuous variables).
Multivariate association analyses with MI risk, genotype frequencies were assessed by means of multivariate methods based on logistic regression analysis, the odds ratios (ORs) and 95% confidence intervals (CIs) for the effect of SNPs on MI risk adjusted by age, sex, smoking, drinking, hypertension, diabetes and hyperlipidemia. Association analyses between SNPs and blood lipid profiles were performed by one-way analysis of variance (ANOVA). The statistical analyses were performed using the SPSS software (version 21). A P value of less than 0.05 was used as the criterion of statistical significance.
Characteristics of the study population
The characteristics of MI cases and controls
Controls (n = 650)
Cases (n =285)
61.61 ± 12.22
62.07 ± 11.99
Systolic BP (mm Hg)
132.53 ± 18.98
140.02 ± 19.16
Diastolic BP (mm Hg)
72.86 ± 10.47
75.66 ± 11.56
5.81 ± 1.91
6.64 ± 1.72
1.49 ± 0.82
2.06 ± 0.97
Total cholesterol (mmol/L)
4.62 ± 1.16
4.71 ± 1.21
LDL cholesterol (mmol/L)
2.63 ± 0.92
3.03 ± 0.97
HDL cholesterol (mmol/L)
1.37 ± 0.67
1.18 ± 0.36
Multivariate associations of three SNPs with the risk of MI
Primary information for rs2302685, rs6687605 and rs13306731 SNPs
Chr Pos (Genome Build 104.0)
MAFa for Chinese (CHB) in HapMap
MAF in our controls (n = 650)
P Value for HWEb test in our controls
Multivariate associations of the SNPs with the risk of MI
Controls (n = 650)
Cases (n = 285)
OR (95% CI)a
CT + CC
CT + TT
GA + GG
Stratification analyses of LRP6 rs2302685 polymorphism and risk of MI
Multivariate associations of the rs2302685 in LRP6 gene with the risk of MI by further stratification for age
Controls no. (%)
Cases no. (%)
OR (95% CI)a
n = 297
n = 130
CT + CC
> 60 y
n = 353
n = 155
CT + CC
Association analysis between LRP6 rs2302685 polymorphism and LDL-C levels
ANOVA analysis of the association between rs2302685 in LRP6 gene and the LDL-C, HDL-C, TC and TG levels by further stratification for age
CT + CC
CT + CC
LDL cholesterol (mmol/L)
2.72 ± 1.00
3.00 ± 1.04
2.76 ± 0.91
2.63 ± 0.86
HDL cholesterol (mmol/L)
1.36 ± 0.83
1.31 ± 0.40
1.28 ± 0.39
1.29 ± 0.36
Total cholesterol (mmol/L)
4.65 ± 1.18
4.93 ± 1.24
4.63 ± 1.17
4.37 ± 1.04
1.79 ± 1.04
1.68 ± 1.00
1.57 ± 0.77
1.56 ± 0.73
The principal pathogenesis of MI is the disruption of coronary atherosclerotic plaques , which caused by both individual’s genetic makeup and various environmental factors. Previous studies have demonstrated the effects of LRP6 in early coronary artery disease and abnormal blood lipids including hypercholesterolemia [12–14], indicating the important role of LRP6 in the MI development. Nonetheless, the association between SNPs in LRP6 gene and MI risk is still largely unknown. In this study, we performed a genetic association analysis on the three SNPs (rs2302685 in LRP6, rs6687605 in LDLRAP1 and rs13306731 in SOAT1), and revealed that the LRP6 rs2302685 polymorphism was associated with increased risk of MI in a Chinese Han population, and the association was more remarkable among younger subjects (≤60 years old), which might potentially due to the enhanced LDL-C levels. Taken together, our study suggested that LRP6 rs2302685 might play an important role in the MI pathogenesis.
Though rs2302685 has been considered as a common functional LRP6 polymorphism, and is significantly associated with several human diseases such as Alzheimer’s disease , the effects of this polymorphism on MI risk is still unknown. Nonetheless, Sarzani et al. has reported that the rs2302685 was strongly related to carotid artery atherosclerosis (CAA) in hypertensive patients, indicating that C allele of LRP6 rs2302685 might be an independent risk factor for CAA (OR = 2.08, 95% CI = 1.27-3.41, P = 0.003) . Carotid artery atherosclerosis is closely associated with arterial cardiovascular events, and is a strong predictor of future myocardial infarction, which might share common risk factors [35, 36]. Our data that rs2302685 endowed C allele carriers with significant increased MI risk was in consistent with the results from the above association analysis between rs2302685 and CAA.
Our stratified analyses revealed that the increased risk of LRP6 rs2302685 polymorphism in MI was more evident among younger subjects (≤60 years old), whereas no significant association was observed from the group older than 60 years old (Table 4). In addition, LRP6 rs2302685 only exhibited an association with elevated LDL-C levels in younger individuals, but not in total or older subjects. Weak immune system and relative high level exposure to environmental risk factors in older individuals may account for these. The potential risk of MI in older subjects is more likely due to the aging effects rather than direct genetic effects. Thus, the LRP6 rs2302685 polymorphism might be more influential in early-onset MI, which was similar as the effects of LRP6 R611C variant on early-onset CAD development in an Iranian family .
Previous investigations have demonstrated that LRP6, as a component of LDL cholesterol trafficking complex, was involved in direct LDL uptake ; and the elevated LDL-C levels in LRP6 R611C mutation carriers was likely due to the reduced LDL clearance capacity . Moreover, Tomaszewsk et al. unveiled that T allele of LRP6 rs10845493 polymorphism was associated with 0.14 mmol/L increase in LDL-C levels (SE = 0. 05, P = 0.0038) . In consistent with above findings, our data revealed that the LDL-C levels of the individuals carrying CT/CC genotype were higher than the TT genotype carriers among younger individuals (≤60 years old) (Table 5), which provided a reasonable explanation to the enhanced effects of rs2302685 on MI pathogenesis in younger subjects.
Several limitations herein in this case–control study need to be addressed. First, the case subjects and controls enrolled from hospitals may not represent the general population. Nonetheless, the genotype distribution of the controls was in Hardy-Weinberg equilibrium. Second, the moderate sample size of our study limited the statistical power, especially in the case subjects. Finally, further studies in different population could help to verify the true significance of the association between the rs2302685 polymorphism and the risk of MI. However, our observations provided valuable insights and interesting information and might serve to guide future studies in this area.
In aggregate, our study firstly unveiled that the C allele of LRP6 rs2302685 was associated with an increased risk of MI in a Chinese population, and the association was more evident among younger subjects, which potentially due to the elevated LDL-C levels. Further studies with larger sample size and in diverse ethnic populations are required to confirm the general validity of our findings.
- LRP6 :
Low density lipoprotein receptor-related protein 6
Single nucleotide polymorphism
Coronary artery disease
Polymerase chain reaction-ligase detection reaction
Low density lipoprotein cholesterol
High density lipoprotein cholesterol.
We thanks to the First People’s Hospital of Foshan and the Affiliated Hospital of Guangdong Medical College, Guangdong Province, China, for their kind assistance in collecting the samples and data. This work was supported by grants from the National Natural Science Foundation of China (81370456), the Natural Science Foundation of Guangdong Province (S2012010008219).
- Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, Keltai M, Diaz R, Rangarajan S, Yusuf S, Investigators I: Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J. 2008, 29: 932-940. 10.1093/eurheartj/ehn018View ArticlePubMed
- Zhang XH, Lu ZL, Liu L: Coronary heart disease in China. Heart. 2008, 94: 1126-1131. 10.1136/hrt.2007.132423View ArticlePubMed
- Donnan SP, Ho SC, Woo J, Wong SL, Woo KS, Tse CY, Chan KK, Kay CS, Cheung KO, Mak KH: Risk factors for acute myocardial infarction in a southern Chinese population. Ann Epidemiol. 1994, 4: 46-58. 10.1016/1047-2797(94)90042-6View ArticlePubMed
- Austin MA, Hutter CM, Zimmern RL, Humphries SE: Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol. 2004, 160: 421-429. 10.1093/aje/kwh237View ArticlePubMed
- Steinberg D: Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. J Lipid Res. 2005, 46: 179-190.View ArticlePubMed
- Kallel A, Sediri Y, Sbai MH, Mourali MS, Feki M, Elasmi M, Taieb SH, Sanhaji H, Souheil O, Mechmeche R, Jemaa R, Kaabachi N: The paraoxonase L55M and Q192R gene polymorphisms and myocardial infarction in a Tunisian population. Clin Biochem. 2010, 43: 1461-1463. 10.1016/j.clinbiochem.2010.08.029View ArticlePubMed
- Ghaderian SM, Akbarzadeh Najar R, Tabatabaei Panah AS: Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coron Artery Dis. 2010, 21: 330-335. 10.1097/MCA.0b013e32833ce065View ArticlePubMed
- Fujimaki T, Kato K, Yokoi K, Oguri M, Yoshida T, Watanabe S, Metoki N, Yoshida H, Satoh K, Aoyagi Y, Nozawa Y, Kimura G, Yamada Y: Association of genetic variants in SEMA3F, CLEC16A, LAMA3, and PCSK2 with myocardial infarction in Japanese individuals. Atherosclerosis. 2010, 210: 468-473. 10.1016/j.atherosclerosis.2009.11.050View ArticlePubMed
- Chen S, Bubeck D, MacDonald BT, Liang WX, Mao JH, Malinauskas T, Llorca O, Aricescu AR, Siebold C, He X, Jones EY: Structural and functional studies of LRP6 ectodomain reveal a platform for Wnt signaling. Dev Cell. 2011, 21: 848-861. 10.1016/j.devcel.2011.09.007PubMed CentralView ArticlePubMed
- Liu CC, Prior J, Piwnica-Worms D, Bu G: LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci U S A. 2010, 107: 5136-5141. 10.1073/pnas.0911220107PubMed CentralView ArticlePubMed
- Kokubu C, Heinzmann U, Kokubu T, Sakai N, Kubota T, Kawai M, Wahl MB, Galceran J, Grosschedl R, Ozono K, Imai K: Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis. Development. 2004, 131: 5469-5480. 10.1242/dev.01405View ArticlePubMed
- Manolagas SC, Almeida M: Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol. 2007, 21: 2605-2614. 10.1210/me.2007-0259View ArticlePubMed
- Clevers H, Nusse R: Wnt/beta-catenin signaling and disease. Cell. 2012, 149: 1192-1205. 10.1016/j.cell.2012.05.012View ArticlePubMed
- Joiner DM, Ke J, Zhong Z, Xu HE, Williams BO: LRP5 and LRP6 in development and disease. Trends Endocrinol Metab. 2013, 24: 31-39. 10.1016/j.tem.2012.10.003PubMed CentralView ArticlePubMed
- Xu Y, Gong W, Peng J, Wang H, Huang J, Ding H, Wang DW: Functional analysis LRP6 novel mutations in patients with coronary artery disease. PLoS One. 2014, 9: e84345- 10.1371/journal.pone.0084345PubMed CentralView ArticlePubMed
- Mani A, Radhakrishnan J, Wang H, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP: LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science. 2007, 315: 1278-1282. 10.1126/science.1136370PubMed CentralView ArticlePubMed
- Keramati AR, Singh R, Lin A, Faramarzi S, Ye ZJ, Mane S, Tellides G, Lifton RP, Mani A: Wild-type LRP6 inhibits, whereas atherosclerosis-linked LRP6R611C increases PDGF-dependent vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A. 2011, 108: 1914-1918. 10.1073/pnas.1019443108PubMed CentralView ArticlePubMed
- Zhao Z, Pompey S, Dong H, Weng J, Garuti R, Michaely P: S-nitrosylation of ARH is required for LDL uptake by the LDL receptor. J Lipid Res. 2013, 54: 1550-1559. 10.1194/jlr.M033167PubMed CentralView ArticlePubMed
- Garuti R, Jones C, Li WP, Michaely P, Herz J, Gerard RD, Cohen JC, Hobbs HH: The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits. J Biol Chem. 2005, 280: 40996-41004. 10.1074/jbc.M509394200View ArticlePubMed
- Mishra SK, Watkins SC, Traub LM: The autosomal recessive hypercholesterolemia (ARH) protein interfaces directly with the clathrin-coat machinery. Proc Natl Acad Sci U S A. 2002, 99: 16099-16104. 10.1073/pnas.252630799PubMed CentralView ArticlePubMed
- Kang RS, Folsch H: ARH cooperates with AP-1B in the exocytosis of LDLR in polarized epithelial cells. J Cell Biol. 2011, 193: 51-60. 10.1083/jcb.201012121PubMed CentralView ArticlePubMed
- Pisciotta L, Priore Oliva C, Pes GM, Di Scala L, Bellocchio A, Fresa R, Cantafora A, Arca M, Calandra S, Bertolini S: Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison. Atherosclerosis. 2006, 188: 398-405. 10.1016/j.atherosclerosis.2005.11.016View ArticlePubMed
- Arca M, Zuliani G, Wilund K, Campagna F, Fellin R, Bertolini S, Calandra S, Ricci G, Glorioso N, Maioli M, Pintus P, Carru C, Cossu F, Cohen J, Hobbs HH: Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet. 2002, 359: 841-847. 10.1016/S0140-6736(02)07955-2View ArticlePubMed
- Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, Davidson MH, Deanfield JE, Wisniewski LM, Hanyok JJ, Kassalow LM: Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006, 354: 1253-1263. 10.1056/NEJMoa054699View ArticlePubMed
- Rudel LL, Shelness GS: Cholesterol esters and atherosclerosis-a game of ACAT and mouse. Nat Med. 2000, 6: 1313-1314. 10.1038/82110View ArticlePubMed
- Sliskovic DR, Picard JA, Krause BR: ACAT inhibitors: the search for a novel and effective treatment of hypercholesterolemia and atherosclerosis. Prog Med Chem. 2002, 39: 121-171.View ArticlePubMed
- Sediri Y, Kallel A, Feki M, Mourali S, Elasmi M, Abdessalem S, Mechmeche R, Jemaa R, Kaabachi N: Association of a DNA polymorphism of the apolipoprotein AI-CIII-AIV gene cluster with myocardial infarction in a Tunisian population. Eur J Intern Med. 2011, 22: 407-411. 10.1016/j.ejim.2011.03.002View ArticlePubMed
- Abd El-Aziz TA, Mohamed RH, Hashem RM: Association of lipoprotein lipase and apolipoprotein C-III genes polymorphism with acute myocardial infarction in diabetic patients. Mol Cell Biochem. 2011, 354: 141-150. 10.1007/s11010-011-0813-6View ArticlePubMed
- Izar MC, Helfenstein T, Ihara SS, Relvas WG, Santos AO, Fischer SC, Pinto LE, Lopes IE, Pomaro DR, Fonseca MI, Bodanese LC, Moriguchi EH, Saraiva JF, Introcaso L, Souza AD, Scartezini M, Torres KP, Zagury L, Jardim PC, Costa EA, Tacito LH, Forti A, Magalhaes ME, Chacra AR, Bertolami MC, Loures-Vale AA, Barros MA, Xavier HT, Lyra R, Argamanijan D: Association of lipoprotein lipase D9N polymorphism with myocardial infarction in type 2 diabetes: the genetics, outcomes, and lipids in type 2 diabetes (GOLD) study. Atherosclerosis. 2009, 204: 165-170. 10.1016/j.atherosclerosis.2008.08.006View ArticlePubMed
- Lambert JC, Brousseau T, Defosse V, Evans A, Arveiler D, Ruidavets JB, Haas B, Cambou JP, Luc G, Ducimetiere P, Cambien F, Chartier-Harlin MC, Amouyel P: Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study. Hum Mol Genet. 2000, 9: 57-61. 10.1093/hmg/9.1.57View ArticlePubMed
- Xiong XD, Luo XP, Cheng J, Liu X, Li EM, Zeng LQ: A genetic variant in pre-miR-27a is associated with a reduced cervical cancer risk in southern Chinese women. Gynecol Oncol. 2014, 132: 450-454. 10.1016/j.ygyno.2013.12.030View ArticlePubMed
- Wang JC, Normand SL, Mauri L, Kuntz RE: Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation. 2004, 110: 278-284. 10.1161/01.CIR.0000135468.67850.F4View ArticlePubMed
- De Ferrari GV, Papassotiropoulos A, Biechele T, Wavrant De-Vrieze F, Avila ME, Major MB, Myers A, Saez K, Henriquez JP, Zhao A, Wollmer MA, Nitsch RM, Hock C, Morris CM, Hardy J, Moon RT: Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci U S A. 2007, 104: 9434-9439. 10.1073/pnas.0603523104PubMed CentralView ArticlePubMed
- Sarzani R, Salvi F, Bordicchia M, Guerra F, Battistoni I, Pagliariccio G, Carbonari L, Dessi-Fulgheri P, Rappelli A: Carotid artery atherosclerosis in hypertensive patients with a functional LDL receptor-related protein 6 gene variant. Nutr Metab Cardiovasc Dis. 2011, 21: 150-156. 10.1016/j.numecd.2009.08.004View ArticlePubMed
- Friedlander AH: Carotid artery calcifications are a risk indicator for both myocardial infarction and stroke. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013, 115: 700-View ArticlePubMed
- Hald EM, Lijfering WM, Mathiesen EB, Johnsen SH, Lochen ML, Njolstad I, Wilsgaard T, Rosendaal FR, Braekkan SK, Hansen JB: Carotid atherosclerosis predicts future myocardial infarction but not venous thromboembolism: the Tromso study. Arterioscler Thromb Vasc Biol. 2014, 34: 226-230. 10.1161/ATVBAHA.113.302162View ArticlePubMed
- Liu W, Mani S, Davis NR, Sarrafzadegan N, Kavathas PB, Mani A: Mutation in EGFP domain of LDL receptor-related protein 6 impairs cellular LDL clearance. Circ Res. 2008, 103: 1280-1288. 10.1161/CIRCRESAHA.108.183863PubMed CentralView ArticlePubMed
- Tomaszewski M, Charchar FJ, Barnes T, Gawron-Kiszka M, Sedkowska A, Podolecka E, Kowalczyk J, Rathbone W, Kalarus Z, Grzeszczak W, Goodall AH, Samani NJ, Zukowska-Szczechowska E: A common variant in low-density lipoprotein receptor-related protein 6 gene (LRP6) is associated with LDL-cholesterol. Arterioscler Thromb Vasc Biol. 2009, 29: 1316-1321. 10.1161/ATVBAHA.109.185355PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.